Laidlaw Scholars Ventures

Laidlaw Scholars Ventures (LSV) is a venture capital firm established in 2021 and based in London, United Kingdom. The firm focuses on investing in start-ups that are founded and operated by Laidlaw Scholars. LSV targets businesses in sectors such as business-to-business technology, software as a service (SaaS), sustainable energy, and media, with a geographic emphasis on the United Kingdom, Ireland, and the United States.

Niall Santamaria

Chief Investment Officer

6 past transactions

CardiaTec Biosciences

Seed Round in 2024
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Guava

Pre Seed Round in 2023
Guava is a digital bank tailored specifically for black small business owners. Its mission is to bridge the racial wealth gap by offering equitable financial products and services designed to meet the unique needs of its target clientele. The platform provides access to industry experts, educational resources like workshops and webinars, and efficient mobile fund transfers, all while fostering nationwide networking opportunities for users with no concealed charges.

ProMotion Rewards

Pre Seed Round in 2022
ProMotion Rewards is a company that provides a marketing platform aimed at bridging the gap between consumer brands and their customers. By leveraging data and insights from consumer behavior, the company enables brands in the consumer packaged goods, retail, and e-commerce sectors to enhance their performance in the marketplace. Their platform allows consumers to earn rewards by scanning everyday shopping receipts, thus incentivizing customer engagement while providing brands with the ability to directly attribute their marketing and trade expenditures to actual sales outcomes. This closed-loop environment fosters meaningful connections between brands and their customers, helping to drive improved marketing effectiveness and business results.

Sable

Seed Round in 2022
Sable is a digital banking company focused on providing accessible financial services to underserved individuals, particularly those who are new to the U.S. or lack a traditional credit history. The company offers credit-building cards, fee-free bank accounts, and debit cards that can be obtained quickly without requiring a Social Security number or U.S. address. Sable's products include a premium card designed for faster credit building through enhanced reporting on multiple data points. Additionally, the company provides a gamified path to unsecured credit, guiding customers through tangible milestones to improve their financial standing.

Sool

Seed Round in 2022
Sool is a producer of Korean alcoholic beverages, specializing in natural, gluten-free drinks that are low in alcohol and carbonated. The company offers a diverse range of products, including unfiltered rice beer known as Makgeolli and Soku, a ready-to-drink cocktail made with soju, Korea's most popular spirit. Sool's beverages are crafted from natural ingredients, providing consumers with options that are slightly sweet, fizzy, and tangy, appealing to those seeking an easy-to-sip experience. The product lineup includes various flavors and packs, such as Makku coffee and fruit-flavored packs, as well as a selection of Soku variety packs, catering to a wide array of preferences among alcoholic beverage consumers.

CardiaTec Biosciences

Pre Seed Round in 2022
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.